We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+42.89%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$4.69B
AUM Growth
+$937M
Cap. Flow
+$184M
Cap. Flow %
3.93%
Top 10 Hldgs %
46.5%
Holding
101
New
13
Increased
10
Reduced
7
Closed
20

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$110M
2
THRD
Third Harmonic Bio
THRD
+$62.6M
3
COGT icon
Cogent Biosciences
COGT
+$55M
4
FULC icon
Fulcrum Therapeutics
FULC
+$50.1M
5
BIIB icon
Biogen
BIIB
+$44.7M

Top Sells

Rank Stock Value
1
VERU icon
Veru
VERU
+$89.3M
2
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$61.3M
3
NTRA icon
Natera
NTRA
+$46.4M
4
DYN icon
Dyne Therapeutics
DYN
+$19.3M
5
GH icon
Guardant Health
GH
+$19.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.68%
2 Financials 0.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOWL icon
51
Werewolf Therapeutics
HOWL
$20.1M
$19.4M 0.41%
4,291,881
– –
ICVX
52
DELISTED
Icosavax, Inc. Common Stock
ICVX
$18.8M 0.4%
5,963,565
– –
VRDN icon
53
Viridian Therapeutics
VRDN
$2.13B
$18M 0.39%
+880,000
New +$15.8M
RLAY icon
54
Relay Therapeutics
RLAY
$4.26B
$16.1M 0.34%
717,618
+168,563
+31% +$3.7M
DALS
55
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$14.6M 0.31%
1,500,000
– –
BLSA
56
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$12.5M 0.27%
1,250,000
– –
PRDS
57
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$11.4M 0.24%
6,175,038
– –
ACHL
58
DELISTED
Achilles Therapeutics
ACHL
$11.3M 0.24%
5,014,687
– –
FLACU
59
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$9.98M 0.21%
1,000,000
– –
ARYE
60
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$9.8M 0.21%
1,000,000
– –
CNTB
61
Connect Biopharma Holdings
CNTB
$130M
$9.02M 0.19%
6,991,003
– –
WHWK
62
Whitehawk Therapeutics
WHWK
$196M
$8.34M 0.18%
590,218
+207,190
+54% +$2.72M
FVAM
63
DELISTED
5:01 Acquisition Corp
FVAM
$7.5M 0.16%
750,000
– –
CNCE
64
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$7.29M 0.16%
1,088,296
-2,218,907
-67% -$13.5M
DBVT
65
DBV Technologies
DBVT
$804M
$6.59M 0.14%
+372,474
New +$8.63M
OBIO icon
66
Orchestra BioMed
OBIO
$247M
$6.04M 0.13%
610,283
-14,717
-2% -$146K
SLDB icon
67
Solid Biosciences
SLDB
$790M
$5.77M 0.12%
824,525
– –
LONA
68
LeonaBio Inc
LONA
$70.2M
$5.58M 0.12%
187,800
– –
DNTH icon
69
Dianthus Therapeutics
DNTH
$6.04B
$5.06M 0.11%
+224,255
New +$6.14M
IOBT
70
DELISTED
IO Biotech
IOBT
$5.04M 0.11%
1,857,755
– –
TNYA icon
71
Tenaya Therapeutics
TNYA
$158M
$4.65M 0.1%
1,602,009
-1,949,499
-55% -$9.1M
SYBX
72
DELISTED
Synlogic
SYBX
$4.39M 0.09%
307,894
-80,497
-21% -$1.23M
BDTX icon
73
Black Diamond Therapeutics
BDTX
$99.4M
$4.38M 0.09%
2,589,904
– –
CVRX icon
74
CVRx
CVRX
$146M
$2.57M 0.05%
275,000
– –
ENTX icon
75
Entera Bio
ENTX
$146M
$2.17M 0.05%
2,082,372
-270,628
-12% -$408K
1 2
3
4 5

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, RA Capital Management held 101 positions worth $4.69B, up 25% from $3.75B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

RA Capital Management deployed $184M of net new capital in Q3 2022, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was Legend Biotech: 2,338,610 shares worth $95.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Concert Pharmaceuticals, Inc., an estimated $13.5M trimmed.

  • RA Capital Management's largest Q3 2022 buy was Legend Biotech: 2,338,610 shares worth $95.4M.
  • RA Capital Management added most to Biogen in Q3 2022, an estimated $44.7M increase.
  • RA Capital Management's biggest Q3 2022 reduction was Concert Pharmaceuticals, Inc., cutting an estimated $13.5M.
  • RA Capital Management fully exited Veru in Q3 2022, selling an estimated $89.3M.
  • RA Capital Management's ten largest holdings make up 46% of its $4.69B portfolio in Q3 2022.
  • RA Capital Management opened 13 new positions and closed 20 in Q3 2022.
  • RA Capital Management's portfolio value rose 25% quarter-over-quarter to $4.69B.

Based on RA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.